Full data will be released at AAN in april but here is the news release:
TYSABRI-R- Two-Year Monotherapy Trial Demonstrates Significant Impact on Disability Progression and Relapse Rate in Multiple Sclerosis
Thursday February 17, 2:30 am ET
CAMBRIDGE, Mass. & DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 17, 2005--
Data Show 42% Reduction in the Risk of Disability Progression and Sustained 67% Reduction in Relapse Rate
Biogen Idec (NASDAQ: BIIB - News) and Elan Corporation, plc (NYSE: ELN - ...